Apolipoprotein C-III: From Pathophysiology to Pharmacology

被引：153

作者：

Norata, Giuseppe Danilo ^{[1
,2
]}

Tsimikas, Sotirios ^{[3
]}

Pirillo, Angela ^{[2
,4
]}

Catapano, Alberico L. ^{[1
,4
]}

机构：

[1] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy

[2] Osped Bassini, Ctr Study Atherosclerosis, Cinisello Balsamo, Italy

[3] Univ Calif San Diego, Dept Med, Div Cardiovasc Med, La Jolla, CA 92093 USA

[4] IRCCS Multimed, Milan, Italy

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2015年 / 36卷 / 10期

关键词：

TRIGLYCERIDE-RICH LIPOPROTEINS; LOW-DENSITY-LIPOPROTEIN; RECEPTOR-ALPHA/GAMMA AGONIST; OMEGA-3-ACID ETHYL-ESTERS; B-CONTAINING LIPOPROTEINS; CORONARY-ARTERY-DISEASE; OF-FUNCTION MUTATIONS; FREE FATTY-ACIDS; INSULIN-RESISTANCE; APOC-III;

D O I：

10.1016/j.tips.2015.07.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Apolipoprotein C-III (apoC-III) has a critical role in the metabolism of triglyceride (TG)-rich lipoproteins (TRLs). Animal models lacking the APOC3 gene exhibit reduced plasma TG levels, whereas the overexpression of APOC3 leads to increased TG levels. In humans, loss-of-function mutations in APOC3 are associated with reduced plasma TG levels and reduced risk for ischemic vascular disease and coronary heart disease. Several hypolipidemic agents have been shown to reduce apoC-Ill, including fibrates and statins, and antisense technology aimed at inhibiting APOC3 mRNA to decrease the production of apoC-III is currently in Phase III of clinical development. Here, we review the pathophysiological role of apoC-III in TG metabolism and the evidence supporting this apolipoprotein as an emerging target for hypertriglyceridemia (HTG) and associated cardiovascular disorders.

引用

页码：675 / 687

页数：13

共 112 条

[1] MECHANISM OF HYPERTRIGLYCERIDEMIA IN HUMAN APOLIPOPROTEIN-(APO)-CIII TRANSGENIC MICE - DIMINISHED VERY LOW-DENSITY-LIPOPROTEIN FRACTIONAL CATABOLIC RATE ASSOCIATED WITH INCREASED APO-CIII AND REDUCED APO-E ON THE PARTICLES [J].